Boehringer, VTU Technology renew deal for new therapeutic proteins
The agreement will give Boehringer access to VTU’s yield-enhancing Pichia pastoris expression platform to develop and manufacture therapeutic proteins. The platform is based on VTU’s AOX1 promoter libraries
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.